Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...
A new experimental drug, Nerandomilast, has shown potential in reducing lung inflammation and fibrosis in preclinical models of Idiopathic Inflammatory Myopathy–Associated Interstitial Lung Disease ...
Morning Overview on MSN
Study links a gut bacterium to 29% greater muscle strength
A specific gut bacterium found in human stool samples is linked to significantly stronger muscles in both young and older adults, according to a peer-reviewed study published in the journal Gut. Older ...
Morning Overview on MSN
Animal muscle power sparks new biomaterials for farming, fashion & future medicine
Engineers at Washington University in St. Louis have developed a new class of protein-based fibers modeled on the aligned structure of animal skeletal muscle, producing materials that resist ...
Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater ...
"Fast Track designation is an important regulatory milestone for PBGENE-DMD and reflects the significant unmet need in DMD," said Michael Amoroso, Chief Executive Officer of Precision BioSciences. "We ...
A synthetic tripeptide inspired by snake venom is opening new investigative routes into cellular signalling and structural ...
Satellos Bioscience Inc. ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will ...
The arterial vasculature is the second most frequently calcified structure in the human body after the skeleton. Calcification of the aorta and aortic valves occurs in most individuals in westernized ...
Lean Drops, an innovative liquid dietary supplement targeting metabolic function and appetite regulation, has officially ...
ITF Therapeutics LLC, the U.S. rare disease affiliate of Italfarmaco, today announced the presentation of ten abstracts at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results